Incyte presents EADV data for Incyte stock

Published on 10/01/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 37.70 percent to USD 1.67 billion. Incyte stock costs EUR 107.55 on October 1, 2026 versus EUR 107.10, a 0.42 percent change.

Schwarzweiß-Dokumentarfoto einer Forscherin mit Laborampullen — Incyte Forscherin prüft Reagenzgläser in Schwarzweiß-Reportage, dokumentarisches Symbol für ISIN US45337C1027 Biotechnologie, Illustration mit AI erstellt.

Incyte (ISIN US45337C1027) was trading at EUR 107.55 at Lang & Schwarz on October 1, 2026 at 10:13 a.m. CEST, plus 0.42 percent versus the prior close of EUR 107.10. The company is presenting inflammation and autoimmunity research at the European Academy of Dermatology and Venereology Congress, with the event running from September 30 through October 3, 2026, according to Incyte on September 22, 2026.

Research portfolio reaches Vienna

The EADV program includes one oral presentation and multiple poster presentations covering atopic dermatitis, hidradenitis suppurativa, prurigo nodularis and vitiligo. Incyte's release identifies ruxolitinib cream and povorcitinib among the programs represented, giving the event a direct link to the company's inflammation and autoimmunity pipeline.

The October 1 oral session addresses atopic dermatitis and life-course disruption, while the September 30 poster sessions included 24-week safety and pharmacokinetic results from the TRuE-AD4 study. The schedule places commercial products and late-stage clinical programs side by side, making the congress relevant to both current sales and future launches.

Second-quarter growth sets the benchmark

Incyte reported USD 1.67 billion of revenue in the second quarter of 2026, up 37.70 percent year over year, while diluted earnings per share reached USD 2.81, according to Zacks. Jakafi revenue rose 7.00 percent to USD 816.70 million, while Opzelura revenue reached USD 449.70 million, up 173.00 percent year over year.

The earnings mix also sets a demanding comparison for future quarters. Zacks reported that Incyte raised its 2026 net product revenue outlook to USD 5.13 billion to USD 5.26 billion from USD 4.77 billion to USD 4.94 billion, while Opzelura guidance increased to USD 1.05 billion to USD 1.10 billion from USD 750.00 million to USD 790.00 million.

Atebrioz adds a new financial marker

The FDA approval of Atebrioz, developed by Incyte and licensed to Mirum Pharmaceuticals, adds a second recent product milestone. Investing.com reported on September 28, 2026, that H.C. Wainwright raised its target from USD 150.00 to USD 152.00 and maintained a Buy rating. The same report said the approval triggers a USD 25.00 million payment to Incyte.

For market context, the primary listing is Nasdaq under ticker INCY. Incyte's USD 24.60 billion market capitalization and USD 82.82 to USD 132.60 52-week range were reported as of September 30, 2026, while the euro quote remained close to the middle of that range after currency differences are considered.

Incyte stock stays in the trading frame

At Lang & Schwarz, Incyte stock was trading at EUR 107.55 on October 1, 2026 at 10:13 a.m. CEST, versus the prior close of EUR 107.10, for a plus 0.42 percent daily change. The primary Nasdaq listing last showed USD 121.35 on September 30, 2026 at 4:00 p.m. ET, with a USD 82.82 to USD 132.60 52-week range.

The further course of trading is shown by the continuously updated real-time quote of Incyte stock.